BioHarvest Sciences announced a summary of its Q2 2026 earnings call, where the company revised its total revenue guidance for 2026 from the previous $42 million-$48 million down to $37 million-$40 million. Concurrently, the company has secured its first CDMO manufacturing and supply agreement for a rare, high-end flavor, which is expected to generate $20 million-$30 million in revenue during 2027-2028, and reiterated that this flavor molecule will bring in $180 million in revenue over the first five years of the manufacturing period. The company is shifting its strategic focus from direct-to-consumer (D2C) business to building manufacturing capacity and its CDMO division, aiming for consolidated EBITDA breakeven in 2027, and anticipates a significant reduction in full-year CDMO EBITDA loss to $1.5 million-$2.5 million.